Researchers analyzed 730 patients with low-risk, differentiated thyroid cancer with tumors 2 centimeters or less in width. Half of the patients were randomly sorted to receive no radioactive iodine after the procedure while the other half received the radiation. After three years, there was no difference in the two groups when it came to new treatments, relapses, or abnormal biological markers.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
